Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance.
| Title: | Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. |
|---|---|
| Authors: | Shkoda AS; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Gushchin VA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Department of Virology, Biological Faculty, Lomonosov Moscow State University, 119991 Moscow, Russia.; Ogarkova DA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Stavitskaya SV; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Orlova OE; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Kuznetsova NA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Keruntu EN; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Pochtovyi AA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Department of Virology, Biological Faculty, Lomonosov Moscow State University, 119991 Moscow, Russia.; Pukhov AV; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Kleymenov DA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Krzhanovsky VG; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Vasina DV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Shkuratova NV; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Shidlovskaya EV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Gorbunov AL; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Kustova DD; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Department of Virology, Biological Faculty, Lomonosov Moscow State University, 119991 Moscow, Russia.; Mazurina EA; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Kozlova SR; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Soboleva AV; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Grigoriev IV; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Pankratyeva LL; City Clinical Hospital No. 67 Named after. L.A. Vorokhobov of the Moscow City Department, 123423 Moscow, Russia.; Odintsova AS; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Belyaeva ED; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Department of Virology, Biological Faculty, Lomonosov Moscow State University, 119991 Moscow, Russia.; Bessonova AA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Vasilchenko LA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Lupu IP; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Adgamov RR; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Tkachuk AP; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Tokarskaya EA; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Logunov DY; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Gintsburg AL; Federal State Budget Institution 'National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya' of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.; Department of Infectiology and Virology, Federal State Autonomous Educational Institution of Higher Education I M Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119435 Moscow, Russia. |
| Source: | Vaccines [Vaccines (Basel)] 2022 Jun 13; Vol. 10 (6). Date of Electronic Publication: 2022 Jun 13. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI AG |
| Abstract: | Mass vaccination campaigns against COVID-19 affected more than 90% of the population in most developed countries. The new epidemiologic wave of COVID-19 has been ongoing since the end of 2021. It is caused by a virus variant B.1.1.529, also known as "Omicron" and its descendants. The effectiveness of major vaccines against Omicron is not known. The purpose of this study is to evaluate the efficacy of the Sputnik V vaccine. The main goal is to assess its protection against hospitalization in the period of Omicron dominance. We conducted our study based on a large clinical center in Moscow (Russia) where 1112 patients were included. We used the case-population method to perform the calculations. The data we obtained indicate that the Omicron variant causes at least 90% of infections in the studied cohort. The effectiveness of protection against hospitalization with COVID-19 in our study was 85.9% (95% CI 83.0-88.0%) for those who received more than one dose. It was 87.6% (95% CI 85.4-89.5%) and 97.0% (95% CI 95.9-97.8%) for those who received more than two or three doses. The effectiveness in cases of more severe forms was higher than for less severe ones. Thus, present study indicates the high protective efficacy of vaccination against hospitalization with COVID-19 in case of Omicron lineage. |
| References: | Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168); Vaccines (Basel). 2021 Jul 12;9(7):. (PMID: 34358195); Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989); J Virol. 2022 Mar 23;96(6):e0207721. (PMID: 35225672); Med (N Y). 2021 Aug 13;2(8):979-992.e8. (PMID: 34223401); Ann Intern Med. 2021 Oct;174(10):1404-1408. (PMID: 34280332); EClinicalMedicine. 2022 Mar 24;46:101360. (PMID: 35340627); BMJ. 2020 Dec 2;371:m4709. (PMID: 33268462); Vaccines (Basel). 2022 May 21;10(5):. (PMID: 35632574); PeerJ. 2016 Oct 18;4:e2584. (PMID: 27781170); BMJ. 2021 Sep 17;374:n2297. (PMID: 34535470); Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943); N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246); JAMA. 2021 Jul 6;326(1):35-45. (PMID: 34037666); Bull World Health Organ. 1988;66(1):99-105. (PMID: 3260147); Chem Biol Drug Des. 2022 May;99(5):769-788. (PMID: 35184391); N Engl J Med. 2021 Sep 2;385(10):875-884. (PMID: 34233097); PLoS One. 2022 Jan 21;17(1):e0261759. (PMID: 35061722); Clin Microbiol Infect. 2022 Mar;28(3):398-404. (PMID: 34838783); Lancet. 2021 Feb 20;397(10275):671-681. (PMID: 33545094); Lancet. 2022 Jan 29;399(10323):437-446. (PMID: 35065011); Lancet. 2020 Sep 26;396(10255):887-897. (PMID: 32896291); N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609); Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114); Virus Evol. 2022 Mar 05;8(1):veac017. (PMID: 35371558); BMJ. 2021 Dec 3;375:n3011. (PMID: 34862175); Bioinformatics. 2010 Mar 15;26(6):841-2. (PMID: 20110278); Life (Basel). 2022 Jan 28;12(2):. (PMID: 35207482); EClinicalMedicine. 2021 Oct;40:101126. (PMID: 34541480) |
| Contributed Indexing: | Keywords: COVID-19; Omicron; SARS-CoV-2; Sputnik Light; Sputnik V; VOC; vaccine; vaccine effectiveness |
| Entry Date(s): | Date Created: 20220624 Latest Revision: 20220716 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9227631 |
| DOI: | 10.3390/vaccines10060938 |
| PMID: | 35746546 |
| Database: | MEDLINE |
Journal Article